Filtered By:
Condition: Polyps

This page shows you your search results in order of date. This is page number 8.

Order by Relevance | Date

Total 2492 results found since Jan 2013.

Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study
Conclusion: Baseline eosinophil count, eosinophil/lymphocyte ratio, and FEV1 (%) were found to be important predictors of response to mepolizumab treatment. Further studies are needed to define the characterization of mepolizumab responders in the real world.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - March 30, 2023 Category: Allergy & Immunology Source Type: research

The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma
AbstractPurpose of ReviewThe present review aims to systematically assess published data to elucidate benralizumab efficacy on nasal outcomes in comorbid patients.Recent FindingsChronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the nasal cavity often associated with severe asthma (SA), contributing to a global disease burden in asthmatics. The two pathologies share common underlying mechanisms (e.g., type-2 inflammation), which sustain symptoms and poor comorbid patient quality of life. Therefore, it is of primary importance to identify the correct therapeutic option in order to a...
Source: Current Allergy and Asthma Reports - March 30, 2023 Category: Allergy & Immunology Source Type: research

Clinical outcomes of dupilumab therapy in chronic rhinosinusitis with nasal polyps in a Canadian tertiary care rhinology practice
In 2020, dupilumab became the first monoclonal antibody therapy to be approved by Health Canada for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The primary aim of this study was to char...
Source: Allergy, Asthma and Clinical Immunology - March 30, 2023 Category: Allergy & Immunology Authors: Elysia Grose, Alyssa Y. Li and John M. Lee Tags: Research Source Type: research

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
Source: Journal of Asthma and Allergy - March 29, 2023 Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research

Some Macrophages With High Expression of CHOP Undergo Necroptosis in Chronic Rhinosinusitis
CONCLUSION: IL1β induced the apoptotic pathway and minor necroptosis. And ER stress also plays a role in the occurrence of necroptosis in CRSwNP.PMID:36946083 | DOI:10.1177/19458924231163974
Source: American Journal of Rhinology and Allergy - March 22, 2023 Category: ENT & OMF Authors: Min Li Ziming Fu Chenglin Qi Qinying Wang Hui Xie Huabin Li Source Type: research

Calprotectin in Chronic Rhinosinusitis Eosinophil Extracellular Traps
Conclusions: Calprotectin, known to be secreted by neutrophils, in CRS was also expressed in eosinophils. In addition, calprotectin, which functions as an antimicrobial peptide, may play an important role in the innate immune response based on its EETs involvement. Therefore, calprotectin expression could reflect as a disease severity biomarker for CRS.This article is protected by copyright. All rights reserved
Source: International Forum of Allergy and Rhinology - March 18, 2023 Category: Allergy & Immunology Authors: Sang Hyeon Ahn, Kyu Ha Shin, Jun Taek Oh, Sang Chul Park, Min ‐Seok Rha, Soo In Kim BS, Hyung‐Ju Cho, Joo‐Heon Yoon, Chang‐Hoon Kim Tags: ORIGINAL ARTICLE Source Type: research

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
Conclusion In this study, 57% of N-ERD patients tolerated higher doses of aspirin under dupilumab therapy.
Source: European Respiratory Journal - March 16, 2023 Category: Respiratory Medicine Authors: Schneider, S., Poglitsch, K., Morgenstern, C., Quint, T., Gangl, K., Sinz, C., Bartosik, T., Campion, N. J., Liu, D. T., Landegger, L. D., Tu, A., Stanek, V., Rocha-Hasler, M., Bangert, C., Eckl-Dorna, J. Tags: Asthma and allergy Original Articles: Asthma and allergy Source Type: research

Proteomics and metabolomics analysis of nasal lavage fluid in chronic rhinosinusitis with nasal polyps
Source: International Forum of Allergy and Rhinology - March 11, 2023 Category: Allergy & Immunology Authors: Yujuan Yang, Jing Guo, Yao Yao, Jianwei Wang, Jiali Yin, Ying Guo, Cai Wang, Yu Zhang, Xicheng Song Tags: Research Note Source Type: research

Nasal disease with polyps: need for clarity
Source: International Forum of Allergy and Rhinology - March 4, 2023 Category: Allergy & Immunology Authors: Rogerio Pezato, Aldo Cassol Stamm, Richard Douglas, Joseph K Han, Philip G Chen, Carlos Di ógenes Pinheiro Neto, Miguel Soares Tepedino, Narinder Singh, Leonardo Balsalobre, Chang Hwan Ryu, Luciano Gregório, Sharif Amatrafi, Alexandre Wady D Tags: CLINICAL LETTER Source Type: research

Update on Allergic Fungal Rhinosinusitis
Ann Allergy Asthma Immunol. 2023 Feb 26:S1081-1206(23)00126-6. doi: 10.1016/j.anai.2023.02.018. Online ahead of print.ABSTRACTAllergic fungal rhinosinusitis (AFRS) is a unique clinical entity that falls under the broader umbrella of chronic rhinosinusitis with nasal polyps (CRSwNP) with type 2 inflammation. It is characterized by nasal polyposis, production of characteristic thick eosinophilic mucin, and expansile change of involved sinus cavities. The diagnosis is classically made using the Bent and Kuhn criteria. However, recent studies have demonstrated lack of specificity of some major criteria. The need to fulfil all ...
Source: Annals of Allergy, Asthma and Immunology - February 28, 2023 Category: Allergy & Immunology Authors: Andy J Chua Ali Jafar Amber U Luong Source Type: research

Current Understanding of the Role of Eosinophils in CRSwNP and Implications for Treatment with Mepolizumab and Benralizumab
CONCLUSION: Blockade of IL5/IL5R alone would appear to provide limited "real life" clinical benefit in patients with CRSwNP due to the complexities of the pathophysiology of the condition. Therapy aimed at several simultaneous cytokine targets has logic but well-designed trials are unlikely to be forthcoming in the short term due to the financial cost and commercial conflicts of interest.PMID:36848284 | DOI:10.1177/19458924221149270
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: A Simon Carney Peter K Smith Source Type: research

State of the Art Medical Management of Nasal Polyps
CONCLUSIONS: Topical steroid therapy is clearly effective for CRSwNP, and recent studies demonstrate the safety and efficacy of high-dose nasal steroid rinses. Alternate delivery methods for local steroids may be useful for patients who are not responding to or who are noncompliant with conventional intranasal corticosteroid sprays and rinses. Future studies are needed to clarify if oral or topical antibiotics, oral anti-leukotrienes, or other novel therapies are significantly effective in decreasing symptoms and improving the quality of life in patients with CRSwNP.PMID:36848283 | DOI:10.1177/19458924221145256
Source: American Journal of Rhinology and Allergy - February 27, 2023 Category: ENT & OMF Authors: Kelly L Staricha Hawa M Ali Janalee K Stokken Source Type: research